Benaim D, Tétart F, Bauvin O, Delcampe A, Joly P, Muraine M, Gueudry J
Ophthalmology service, Rouen university Hospital., 1, rue de Germont, 76000 Rouen, France.
Dermatology service, Rouen university Hospital, 1, rue de Germont, 76000 Rouen, France.
J Fr Ophtalmol. 2019 Apr;42(4):e147-e151. doi: 10.1016/j.jfo.2019.02.003. Epub 2019 Mar 7.
Atopic keratoconjunctivitis is frequently associated with atopic eyelid dermatitis. It may require topical steroids, the prolonged use of which may cause ocular complications. Tacrolimus is an immunosuppressant used topically on the skin in atopic dermatitis. The purpose of this study is to evaluate the efficacy and tolerability of tacrolimus 0.1% ointment applied to the eyelids in atopic keratoconjunctivitis.
This is a single center, retrospective study carried out between June 2014 and February 2017. Patients presenting with atopic keratoconjunctivitis uncontrolled by first-line medical treatment were included. The main outcome was change in functional symptoms as evaluated by the NEI-VFQ25 and OSDI quality of life scores. Secondary criteria were visual acuity and topical steroids use.
Among the 18 patients included, the mean age was 37.9±16.8years. The first follow-up visit occurred on average 68.3±55.3 days after initiation of treatment. The NEI-VFQ25 score improved significantly for seven of the sub-scores (P<0.05), and the mean OSDI decreased significantly from 52.3±26.2 to 22.0±27.0 (P<0.001), demonstrating a decrease in ocular symptoms. A significant reduction in the number of patients requiring topical steroid treatment was observed. There was no significant change in visual acuity.
Tacrolimus 0.1% ointment applied to the eyelids appears to be an effective treatment in the management of atopic keratoconjunctivitis.
特应性角结膜炎常与特应性眼睑皮炎相关。可能需要局部使用类固醇，而长期使用可能会导致眼部并发症。他克莫司是一种免疫抑制剂，用于特应性皮炎的皮肤局部治疗。本研究的目的是评估0.1%他克莫司软膏用于特应性角结膜炎眼睑治疗的疗效和耐受性。
这是一项于2014年6月至2017年2月间开展的单中心回顾性研究。纳入一线药物治疗无法控制的特应性角结膜炎患者。主要结局是通过NEI-VFQ25和OSDI生活质量评分评估的功能症状变化。次要标准为视力和局部类固醇使用情况。
纳入的18例患者中，平均年龄为37.9±16.8岁。首次随访平均在治疗开始后68.3±55.3天进行。NEI-VFQ25评分中的7个分项显著改善（P<0.05），平均OSDI从52.3±26.2显著降至22.0±27.0（P<0.001），表明眼部症状减轻。观察到需要局部类固醇治疗的患者数量显著减少。视力无显著变化。
0.1%他克莫司软膏用于眼睑似乎是治疗特应性角结膜炎的有效方法。
